Pfizer invests in French gene therapy co.

Mar 20, 2019

Pfizer announced it has acquired a 15 percent stake in Vivet Therapeutics, with an exclusive option to fully acquire the privately-held French gene therapy company.

Pfizer has paid about $51 million upfront and may pay up to $635.8 million in clinical and regulatory milestone payments.

Pfizer is waiting on Vivet's delivery of certain data from an early-stage clinical trial for its VTX-801, an experimental treatment for Wilson disease, a rare disorder that can cause liver disease. The drugmakers plan to collaborate on the development of the treatment. According to Pfizer, bringing together Pfizer’s and Vivet’s expertise in liver-directed AAV gene therapy for metabolic diseases creates an opportunity to develop a breakthrough medicine that can meaningfully improve the lives of patients with Wilson disease. 

Read the press release.

Looking for insights on the current pharma industry? Download the 2018 State of  Pharmaceutical Manufacturing eBook